» Articles » PMID: 33101607

The Autoinhibited State of MKK4: Phosphorylation, Putative Dimerization and R134W Mutant Studied by Molecular Dynamics Simulations

Overview
Specialty Biotechnology
Date 2020 Oct 26
PMID 33101607
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Protein kinases are crucial components of the cell-signalling machinery that orchestrate and convey messages to their downstream targets. Most often, kinases are activated upon a phosphorylation to their activation loop, which will shift the kinase into the active conformation. The Dual specificity mitogen-activated protein kinase kinase 4 (MKK4) exists in a unique conformation in its inactive unphosphorylated state, where its activation segment appears in a stable α-helical conformation. However, the precise role of this unique conformational state of MKK4 is unknown. Here, by all-atom molecular dynamics simulations (MD simulations), we show that this inactive state is unstable as monomer even when unphosphorylated and that the phosphorylation of the activation segment further destabilizes the autoinhibited α-helix. The specific phosphorylation pattern of the activation segment has also a unique influence on MKK4 dynamics. Furthermore, we observed that this specific inactive state is stable as a dimer, which becomes destabilized upon phosphorylation. Finally, we noticed that the most frequent MKK4 mutation observed in cancer, R134W, which role has not been disclosed to date, contributes to the dimer stability. Based on these data we postulate that MKK4 occurs as a dimer in its inactive autoinhibited state, providing an additional layer for its activity regulation.

Citing Articles

Autoinhibited Protein Database: a curated database of autoinhibitory domains and their autoinhibition mechanisms.

Cho D, Lee H, Kim J, Song J, Hwang S, Lee B Database (Oxford). 2024; 2024.

PMID: 39192607 PMC: 11349611. DOI: 10.1093/database/baae085.


First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.

Zwirner S, Abu Rmilah A, Klotz S, Pfaffenroth B, Kloevekorn P, Moschopoulou A Cell. 2024; 187(7):1666-1684.e26.

PMID: 38490194 PMC: 11011246. DOI: 10.1016/j.cell.2024.02.023.


MKK4 Inhibitors-Recent Development Status and Therapeutic Potential.

Katzengruber L, Sander P, Laufer S Int J Mol Sci. 2023; 24(8).

PMID: 37108658 PMC: 10144091. DOI: 10.3390/ijms24087495.


Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.

Zhou S, Yang B, Xu Y, Gu A, Peng J, Fu J J Mol Model. 2022; 28(9):247.

PMID: 35932378 DOI: 10.1007/s00894-022-05254-0.


Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A.

Liu C, Zhang Y, Zhang Y, Liu Z, Mao F, Chai Z Molecules. 2022; 27(14).

PMID: 35889528 PMC: 9317881. DOI: 10.3390/molecules27144655.


References
1.
Ferguson F, Gray N . Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018; 17(5):353-377. DOI: 10.1038/nrd.2018.21. View

2.
Matsumoto T, Kinoshita T, Kirii Y, Tada T, Yamano A . Crystal and solution structures disclose a putative transient state of mitogen-activated protein kinase kinase 4. Biochem Biophys Res Commun. 2012; 425(2):195-200. DOI: 10.1016/j.bbrc.2012.07.066. View

3.
Ahn Y, Yang Y, Gibbons D, Creighton C, Yang F, Wistuba I . Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Mol Cell Biol. 2011; 31(21):4270-85. PMC: 3209326. DOI: 10.1128/MCB.05562-11. View

4.
Barcelo C, Paco N, Morell M, Alvarez-Moya B, Bota-Rabassedas N, Jaumot M . Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. Cancer Res. 2013; 74(4):1190-9. DOI: 10.1158/0008-5472.CAN-13-1750. View

5.
Matsumoto T, Kinoshita T, Kirii Y, Yokota K, Hamada K, Tada T . Crystal structures of MKK4 kinase domain reveal that substrate peptide binds to an allosteric site and induces an auto-inhibition state. Biochem Biophys Res Commun. 2010; 400(3):369-73. DOI: 10.1016/j.bbrc.2010.08.071. View